ABPI Final Signatory Support
Contractor or fully outsourced signatory cover to keep approvals moving, strengthen claims, and reduce PMCPA risk—without slowing the business.
- Discuss Outsourced Cover
Same-day / next-day review options (by agreement)
Evidence-led claim strengthening (not just “red pen” edits)
Practical support for job bags, meetings, congress and digital
Led by Dr Anzal Qurbain — ABPI Final Medical Signatory • GMC Registered Pharmaceutical Physician • MBA (LBS) • FFPM
What this support delivers
Clearer decisions, faster cycles, stronger rationale—without losing commercial impact.
- Faster approvals through clear signatory-ready rationale
- Stronger claims with clean evidence logic and balance
- Reduced rework via consistent standards across teams
- Lower escalation risk in high-pressure moments (meetings, congress, digital)
Busy brand teams
Medical/compliance teams under capacity pressure
Launch/campaign and congress teams
Digital + PR owners
UK/ROI teams needing ABPI signatory cover
How it works
Choose the model that fits your team and workload.
Each week combines bite-sized learning with real-world application—so you strengthen compliant decision-making, reduce rework, and feel confident defending claims across job bags, meetings, and digital content.
Embedded Contractor Final Signatory
I join your approval workflow as a contracted Final Signatory to support business-as-usual approvals and peak periods (congresses, launches, capacity gaps, leave cover).
• Day-to-day signatory documented
• Live collaboration with originators/reviewers
• Escalation support for difficult claim areas
Outsourced Signatory + Copy Review Service
A structured outsourced model for teams that want reliable turnaround, consistent standards, and an external signatory/advisory layer for materials. (This is the “outsourced approval + advisory” style used by established providers in the market.)
• Defined intake, triage and review pathway
• Clear outputs: approve / approve with changes
• Optional advisory sessions to unblock issues fast
Typical materials reviewed
Core visual aids
Leave pieces, emails, banners, landing pages
Meetings & congress materials (including international congress content)
Advisory board materials (invites, agendas, slides, outputs)
Press releases and corporate announcements
Patient-facing / public comms (where appropriate)
Internal training and field tools (including REP support)
FAQ
Frequently Asked Questions
Embedded support integrates into your day-to-day approval process as a contracted Final Signatory. Outsourced support uses a defined intake/review pathway for materials, giving you predictable turnaround and consistent outputs across teams.
This depends on volume and complexity. We can agree standard turnaround (e.g., 24–72 hours) plus an expedited pathway for priority materials during peak periods.
Both. The goal is compliant and effective. I’ll help tighten claim logic, improve balance, and make materials more approvable—without unnecessary de-powering.
Typically: digital/social ecosystems, press releases, high-impact claims (superiority/first & only), public-facing content, and meeting materials where hospitality/governance wording is unclear.
Yes—especially where UK ABPI standards need to be applied consistently alongside global content and local requirements.
I provide concise rationale notes and repeatable standards so decisions are consistent across teams, topics, and timelines—reducing rework and internal debate.
Yes. If helpful, we can add short enablement sessions to reduce future cycles—e.g., “what good looks like” for claims, job bags, meetings, and digital.
Book a call. Share your typical materials, workflow, volume, and timelines. I’ll propose the best support model and a simple onboarding plan.
Insights and more
News & PMCPA Cases

AI-Enabled MLR in Pharma: Governance First Guide
AI tools can enhance Medical affairs MLR workflows but pose governance challenges. It’s crucial to implement strict controls, maintain compliance with the ABPI Code, and ensure documented human oversight.
AstraZeneca: promotional meeting misclassified and LinkedIn ‘likes/reposts’ led to pre-authorisation promotion and public advertising concerns (AUTH/3729/1/23)
Six complaints against AstraZeneca. Breaches found for a UK meeting treated as non-promotional (certification/PI and ‘cure’ claims) and for LinkedIn engagement promoting an unlicensed medicine and a POM to the public.

Blurred boundaries: Lessons from the Eli Lilly Facebook Breast Cancer Ad (CASE/3869/12/23)
TL;DR: Even a globally reputable company using trusted partners can stumble into serious compliance breaches online. All pharma professionals should be proactive, transparent, and vigilant—especially with third-party digital campaigns. The future of ethical pharmaceutical advertising depends on it. For many in pharma, the digital landscape can feel like quicksand—seemingly solid

The ripple effect of a single click: What Moderna’s mRESVIA PMCPA case really teaches us
Ever wondered how something as innocent as a LinkedIn ‘like’ could pull an entire pharma company into PMCPA hot water? I once underestimated how quickly a digital echo can travel, but the Moderna mRESVIA PMCPA case showed the true power (and risk) of our online footprint. Let’s break down what

LinkedIn landmines: The hidden pitfalls of pharma social media
What 214 Social Media cases taught me about compliance risk I’ve just finished reviewing 214 PMCPA cases where social media played a role. The pattern is undeniable: LinkedIn and other platforms are now a leading source of ABPI Code breaches. And the worrying part? Most of these breaches started with

Beyond the headlines: What the Epidyolex Press Release ruling really teaches pharma teams
Let me take you behind the scenes of a Jazz Pharmaceuticals case that could have happened to any of us. In my early years as a final signatory I found myself agonising over whether mentioning a drug’s brand name too many times in a Press Release could result in a
